Core Viewpoint - The traditional Chinese medicine (TCM) industry in China is experiencing rapid growth, with a market size exceeding 700 billion yuan, but faces challenges such as high planting costs and quality control issues, necessitating an urgent need for a comprehensive upgrade of the entire industry chain [1] Industry Development - Gansu Province, particularly Dingxi City, is a key area for TCM resources, with a stable planting area of over 2 million mu and a total output of more than 500,000 tons [1] - The TCM industry is a strategic pillar for Dingxi, contributing significantly to local income, with farmers earning 22.4% of their disposable income from TCM-related activities [1] Standardization and Efficiency - Dingxi has implemented standardized planting practices, significantly reducing labor costs from one-third to one-tenth of income through mechanization and drone technology [3] - The establishment of a closed-loop system for quality control in TCM planting has been achieved, with 84.2% of TCM being standardized [4] Quality Assurance - Efforts to ensure the quality of TCM materials include the establishment of seed processing plants and the promotion of high-quality seed varieties, resulting in a germination rate of over 98% [4] - The introduction of the "GAP" (Good Agricultural Practices) standard has led to the establishment of 33.02 million mu of compliant TCM bases in Gansu, maintaining a leading position nationally [8] Market and Trade - Dingxi's TCM market has a static storage capacity of 1.4 million tons, with annual trading volumes exceeding 150 million tons and transaction values nearing 30 billion yuan [12] - The establishment of processing workshops and the integration of TCM production and trade have enhanced local economic benefits, with companies like Gansu Tianceng Xingwei Pharmaceutical Co., Ltd. leading the way in the full industry chain development [7][14] Innovation and Product Development - Companies are increasingly focusing on the development of health products, with Gansu Weishuiyuan Pharmaceutical Technology Co., Ltd. expanding its product line to include health series products, contributing to 10% of its sales revenue [15] - The introduction of AI technology in production processes has improved efficiency by 50%, allowing for precise control over product quality [15] Investment and Future Prospects - Recent trade fairs have resulted in significant investment agreements, with 68 projects signed worth 8.966 billion yuan, indicating strong future growth potential in the TCM sector [16]